Finally, metastasis-free survival was reduced in patients with ERBB2+/ER+ breast cancer in which TOM1L1 was also amplified compared with those without TOM1L1 amplification (patients selected from our previous work26) (Fig. 1e). This evidence concerns the gene TOM1L1 and breast cancer.